



BC Cancer Agency

Systemic Therapy Update

Volume 8, Supplement 1 *for health professionals who care for cancer patients* 11 July 2005
Website access at <http://www.bccancer.bc.ca/STUpdate/>

INSIDE THIS ISSUE

- Breaking News: Adjuvant Trastuzumab (Herceptin®) for Breast Cancer – New Policy
- Benefit Drug List - Trastuzumab
- [List of New and Revised Protocols](#) – New: BRAJACTT, BRAJTR, BRJACTTG, BRLAACDT
- [List of New and Revised Pre-Printed Orders](#) – New: BRAJACTT, BRAJTR, BRJACTTG, BRLAACDT

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BREAKING NEWS

[ADJUVANT TRASTUZUMAB \(HERCEPTIN®\) FOR BREAST CANCER – NEW POLICY](#)

The Provincial Systemic Therapy Program of the BC Cancer Agency is pleased to announce the funding of a new program on the use of adjuvant trastuzumab (Herceptin) for high risk HER2 overexpressing breast cancer. This new policy is based on the results of the clinical trials (Intergroup 9831, NSABP B31, HERA) reported at the American Society of Clinical Oncology meeting in May 2005. These showed a benefit in disease free survival and overall survival for the introduction of trastuzumab into adjuvant therapy for women with high risk HER2 overexpressing breast cancer. The new BCCA policy offers the following treatment options:

1. **For newly diagnosed early breast cancer – Doxorubicin/cyclophosphamide (AC) x 4 followed by paclitaxel/trastuzumab (Herceptin®) concurrently for 4 cycles followed by trastuzumab continued for a total of one year of trastuzumab therapy. ([BRAJACTT](#), [BRJACTTG](#))**
2. **For newly diagnosed locally advanced breast cancer – AC x 4 followed by concurrent docetaxel/trastuzumab followed by trastuzumab continued for total of one year of trastuzumab therapy. ([BRLAACDT](#))**
3. **For those already treated and completing in the past 6 months, or on treatment with AC-T, AC-D, CEF or FEC100 follow chemotherapy with trastuzumab x 1 year. ([BRAJTR](#))**

Patients who are not candidates for chemotherapy and are being treated with hormonal therapy only are not candidates for trastuzumab as there is no evidence at this time for the addition of trastuzumab to hormonal treatment in low risk disease.

More details of the eligibility, protocol, policy and preprinted physician's orders are available on the BC Cancer Agency web site (www.bccancer.bc.ca).

BENEFIT DRUG LIST

The following changes have been made to the Benefit Drug List **effective 11 July 2005**:

<i>Drug</i>	<i>Indication</i>	<i>Benefit status</i>
Docetaxel	<ul style="list-style-type: none"> ▪ Treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel (Taxotere®) and trastuzumab (BRLAACDT) 	added as Class II
Paclitaxel	<ul style="list-style-type: none"> ▪ Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (BRAJACTT) ▪ Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (BRJACTTG) 	added as Class I
Trastuzumab	<ul style="list-style-type: none"> ▪ Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (BRAJACTT) ▪ Adjuvant therapy for breast cancer using trastuzumab (Herceptin®) following the completion of chemotherapy (sequential) (BRAJTR) ▪ Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (BRJACTTG) ▪ Treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel (Taxotere®) and trastuzumab (BRLAACDT) 	added as Class II

LIST OF NEW AND REVISED PROTOCOLS

The **BC Cancer Agency Protocol Summaries** are revised on a periodic basis. New and revised protocols for this month are listed below. Protocol codes for treatments requiring “Undesignated Indication” approval are prefixed with the letter **U**.

New protocols:

- **BRAJACTT** new: Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
- **BRAJTR** new: Adjuvant therapy for breast cancer using trastuzumab (Herceptin®) following the completion of chemotherapy (sequential).
- **BRJACTTG** new: Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
- **BRLAACDT** new: Treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel (Taxotere®) and trastuzumab

LIST OF NEW AND REVISED PRE-PRINTED ORDERS

The **INDEX to BC Cancer Agency Pre-printed Orders** are revised on a periodic basis. New and revised pre-printed orders for this month are listed below.

New preprinted orders:

- **BRAJACTT** new: Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
- **BRAJTR** new: Adjuvant therapy for breast cancer using trastuzumab (Herceptin®) following the completion of chemotherapy (sequential).
- **BRJACTTG** new: Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
- **BRLAACDT** new: Treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel (Taxotere®) and trastuzumab

WEBSITE RESOURCES

Reimbursement and Forms: The current Benefit Drug List, Class II forms and Undesignated Indication Application forms are available on the BC Cancer Agency website under Health Professionals Info, Chemotherapy Protocols, Frequently Used Forms (<http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms.htm>).

Cancer Drug Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/cdm/.

Cancer Management Guidelines are available on the BC Cancer Agency website (<http://www.bccancer.bc.ca/CaMgmtGuidelines/>) under Health Professionals Info, Cancer Management Guidelines.

The Cancer Chemotherapy Protocols are available on the BC Cancer Agency website (www.bccancer.bc.ca/ChemoProtocols) under Health Professionals Info, Chemotherapy Protocols.

The Cancer Chemotherapy Pre-Printed Orders are available on the BC Cancer Agency website (www.bccancer.bc.ca/ChemoProtocols) under Health Professionals Info, Chemotherapy Protocols. Pre-Printed Orders are posted at the index page of each tumour site.

Provincial Systemic Therapy Program Policies are available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols, Policies and Procedures.

The Unconventional Cancer Therapies Manual is available on the BC Cancer Agency website www.bccancer.bc.ca under Patient/Public Info, Unconventional Therapies.

EDITORIAL REVIEW BOARD

Mário de Lemos, MSc, PharmD (Editor)
Thanh Vu, PharmD (Assistant Editor)
Cicely Bryce, MD
Johanna Den Duyf, MA

Karen Janes, MSN
Beth Morrison, MLS
Jaya Venkatesh, MHA
Susan Walisser, BSc (Pharm)
Gigi Concon (Editorial Assistant)

IN TOUCH	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604) 877-6000	Toll-Free 1-(800) 663-3333
Communities Oncology Network	Ext 2744	ivenkate@bccancer.bc.ca
Education Resource Nurse	Ext 2638	nursinged@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 6277	lkovacic@bccancer.bc.ca
Drug Information	Ext 6275	druginfo@bccancer.bc.ca
Library / Cancer Information	(604)-675-8003	requests@bccancer.bc.ca
OSCAR Hotline	1-888-355-0355	
Update Editor	Ext 2288	mdelemos@bccancer.bc.ca
Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888) 563-7773
Fraser Valley Centre (FVCC)	(604) 930-2098	Toll-Free 1-(800) 523-2885
Vancouver Centre (VCC)	(604) 877-6000	Toll-Free 1-(800) 663-3333
Vancouver Island Centre (VICC)	(250) 519-5500	Toll-Free 1-(800) 670-3322

BC CANCER AGENCY SYSTEMIC THERAPY UPDATE REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247

OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

E-mail

Fax

	@	
()		Attn:

UPDATES Please Fax-Back information below:

Most items have been hyperlinked for easy access

<input type="checkbox"/> All items for July 2005 (Vol 8 Supplement 1)					
Protocol Summaries: (also available on our website www.bccancer.bc.ca)				Index of Protocol Summaries	
<input type="checkbox"/> BRAJACTT	<input type="checkbox"/> BRAJTR	<input type="checkbox"/> BRJACTTG	<input type="checkbox"/> BRLAACDT	<input type="checkbox"/>	<input type="checkbox"/>
Pre-printed Orders: (also available on our website www.bccancer.bc.ca)				Index of Pre-Printed Orders	
<input type="checkbox"/> BRAJACTT	<input type="checkbox"/> BRAJTR	<input type="checkbox"/> BRJACTTG	<input type="checkbox"/> BRLAACDT	<input type="checkbox"/>	<input type="checkbox"/>
Provincial Systemic Therapy Program Policies					
Reimbursement (also available on our website www.bccancer.bc.ca)					
<input type="checkbox"/> Benefit Drug List (11 July 2005)			<input type="checkbox"/> Class 2 Form (11 July 2005)		
Systemic Therapy Update Index (also available on our website www.bccancer.bc.ca)					
<input type="checkbox"/> Jan-Dec 2000	<input type="checkbox"/> Jan-Dec 2001	<input type="checkbox"/> Jan-Dec 2002	<input type="checkbox"/> Jan-Dec 2003		
<input type="checkbox"/> Jan-Dec 2004					